Biogen will acquire biotechnology company RayThera for $1 billion, targeting growth in the immunology sector.
- Golden Ten Data, June 18 — Biogen announced it has reached an agreement to acquire private biotechnology company RayThera for up to $1 billion, as the pharmaceutical company seeks to expand its immunology research and development pipeline. According to the statement, the deal will include an upfront payment to RayThera shareholders as well as additional milestone payments tied to clinical and regulatory progress. RayThera, headquartered in San Diego, has multiple anti-inflammatory drug candidates, with its lead project expected to enter phase I clinical trials in early Q3 2026. This deal comes amid a wave of biotechnology mergers and acquisitions, as major pharmaceutical giants invest heavily this year to expand their product pipelines.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Client nodes, console, and API were not modified; Chainstack discloses attacker used the ARTEX framework
Elon Musk changes his stance! Tesla (TSLA.US) delays Cybertruck production halt to late summer 2027, just two days after suggesting “refund deposits”
Elon Musk stated that Cybertruck production will be extended until late summer 2027 to clear the order backlog, and Tesla's stock price rose by about 4%.
Japanese dovish policymaker urges "slow down": Price increases are not driven by demand, rate hikes may drag down the economy and inflation
Toichiro Asada, a member of the Bank of Japan's Policy Board, stated that the central bank needs to remain cautious and closely monitor the impact of rate hikes on the economy, as rising interest rates pose the risk of suppressing the inflation trend.
Crypto prices
More
